• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Allakos Inc.

    5/15/25 4:44:38 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLK alert in real time by email
    S-8 POS 1 ny20048850x5-x12_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on May 15, 2025

    Registration No. 333-284250
    Registration No. 333-226247
    Registration No. 333-231276
    Registration No. 333-236631
    Registration No. 333-253701
    Registration No. 333-262749
    Registration No. 333-269134
    Registration No. 333-276392


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-284250
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-226247
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-231276
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236631
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-253701
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-262749
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-269134
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-276392
     
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
     

    ALLAKOS INC.
    (Exact name of registrant as specified in its charter)
     


     
         
    Delaware
     
    45-4798831
    (State or other jurisdiction of
    incorporation or organization)
     
    (IRS employer
    identification number)


    149 Commonwealth Dr Suite 1090
    Menlo Park, California
    (Address of Principal Executive Offices, including Zip Code)
     

     
    2018 Equity Incentive Plan
    2018 Employee Stock Purchase Plan
    2012 Equity Incentive Plan
    (Full title of the Plans)


     
    Michael Hearne
    Chief Financial Officer
    Allakos Inc.
    4747 Executive Drive, Suite 210
    San Diego, California 92121
    (858) 281-5372
    (Name, Address and Telephone Number, including Area Code, of Agent for Service)

    Copies to:

    Ryan A. Murr
    Gibson, Dunn & Crutcher LLP
    One Embarcadero Center Suite 2600
    San Francisco, California 94111
    (415) 393-8200

    Tony Jeffries, Esq.
    Robert T. Ishii, Esq.
    Jennifer Knapp, Esq.
    Ross Tanaka, Esq.
    Wilson Sonsini Goodrich & Rosati P.C.
    650 Page Mill Road
    Palo Alto, California 94304
    (650) 493-9300
     
     


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer
     
    ☐
      
    Accelerated filer
     
    ☐
    Non-accelerated filer
     
    ☒
      
    Smaller reporting company
     
    ☒
           
    Emerging growth company
     
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
     


    EXPLANATORY NOTE
    DEREGISTRATION OF UNSOLD SECURITIES
    These Post-Effective Amendments (these “Post-Effective Amendments”) are filed by Allakos Inc., a Delaware corporation (the “Registrant”), to deregister all shares of the Registrant’s common stock, $0.001 par value per share (the “Shares”), remaining unissued under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) filed by the Registrant with the U.S. Securities and Exchange Commission.
     
     
    •
     
    Registration Statement on Form S-8 (No. 333-226247) pertaining to the registration of (i) 4,000,000 Shares issuable under the 2018 Equity Incentive Plan (the “2018 Plan”), (ii) 500,000 Shares issuable under the 2018 Employee Stock Purchase Plan (the “ESPP”) and (iii) 6,682,030 Shares issuable under the 2012 Equity Incentive Plan (the “2012 Plan”).
      
    •
     
    Registration Statement on Form S-8 (No. 333-231276) pertaining to the registration of (i) 2,105,832 Shares issuable under the 2018 Plan and (ii) 421,166 Shares issuable under the ESPP.
     
    •
     
    Registration Statement on Form S-8 (No. 333-236631) pertaining to the registration of (i) 2,433,390 Shares issuable under the 2018 Plan and (ii) 486,678 Shares issuable under the ESPP.
     
    •
     
    Registration Statement on Form S-8 (No. 333-253701) pertaining to the registration of (i) 2,654,026 Shares issuable under the 2018 Plan and (ii) 530,805 Shares issuable under the ESPP.
     
    •
     
    Registration Statement on Form S-8 (No. 333-262749) pertaining to the registration of (i) 2,731,118 Shares issuable under the 2018 Plan and (ii) 546,223 Shares issuable under the ESPP.
     
    •
     
    Registration Statement on Form S-8 (No. 333-269134) pertaining to the registration of (i) 4,286,792 Shares issuable under the 2018 Plan and (ii) 853,758 Shares issuable under the ESPP.
     
    •
     
    Registration Statement on Form S-8 (No. 333-276392) pertaining to the registration of (i) 4,387,490 Shares issuable under the 2018 Plan and (ii) 877,498 Shares issuable under the ESPP.
     
    •
     
    Registration Statement on Form S-8 (No. 333-284250) pertaining to the registration of (i) 4,482,434 Shares issuable under the 2018 Plan and (ii) 896,486 Shares issuable under the ESPP.
    The Registrant is filing these Post-Effective Amendments to withdraw and remove any unissued and unsold securities issuable by the Registrant pursuant to the above-referenced Registration Statements.
    On April 1, 2025, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub III, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on May 15, 2025, Merger Sub was merged with and into the Registrant with the Registrant surviving as a wholly owned subsidiary of Parent (the “Merger”). In the Merger, each share of Common Stock (the “Shares”) (other than (i) Shares owned or held in the Company’s treasury immediately prior to the Effective Time, (ii) Shares owned directly or indirectly by Parent or Merger Sub immediately prior to the Effective Time and (iii) Shares held by any Allakos stockholder who was entitled to and properly demanded appraisal of such Shares in accordance with Section 262 of the General Corporation Law of the State of Delaware, as amended) was cancelled and converted into the right to receive $0.33 in cash per Share.
    As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities registered under the Registration Statements that remain unsold as of the date hereof and terminates the effectiveness of the Registration Statements.


    SIGNATURE
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 15, 2025. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.
     
         
     
    ALLAKOS INC.
     
         
     
    By: /s/ Michael Hearne
     
     
    Name: Michael Hearne
    Title: Chief Financial Officer
     

    Get the next $ALLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLK

    DatePrice TargetRatingAnalyst
    1/17/2024$6.00 → $1.50Buy → Hold
    Jefferies
    1/16/2024Overweight → Neutral
    Cantor Fitzgerald
    12/18/2023Mkt Perform → Outperform
    William Blair
    12/8/2023$9.00 → $6.00Buy
    Jefferies
    9/27/2023$11.00Mkt Outperform
    JMP Securities
    5/12/2023$6.00 → $9.00Hold → Buy
    Jefferies
    3/7/2023$22.00Overweight
    Piper Sandler
    9/12/2022$2.00Neutral → Underperform
    SMBC Nikko
    More analyst ratings

    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Allakos Inc.

      SC 13G - Allakos Inc. (0001564824) (Subject)

      11/12/24 9:50:12 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allakos Inc.

      SC 13G/A - Allakos Inc. (0001564824) (Subject)

      7/8/24 4:32:41 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

      SC 13G/A - Allakos Inc. (0001564824) (Subject)

      2/14/24 4:58:16 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allakos downgraded by Jefferies with a new price target

      Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously

      1/17/24 7:08:59 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Allakos from Overweight to Neutral

      1/16/24 1:35:19 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos upgraded by William Blair

      William Blair upgraded Allakos from Mkt Perform to Outperform

      12/18/23 6:44:17 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Allakos Inc.

      S-8 POS - Allakos Inc. (0001564824) (Filer)

      5/15/25 4:45:53 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Allakos Inc.

      S-8 POS - Allakos Inc. (0001564824) (Filer)

      5/15/25 4:45:16 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Allakos Inc.

      S-8 POS - Allakos Inc. (0001564824) (Filer)

      5/15/25 4:44:38 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

      SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro

      4/2/25 8:00:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

      SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua

      3/12/25 4:02:00 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

      SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

      2/11/25 11:30:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Financials

    Live finance-specific insights

    See more
    • Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

      – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme

      1/27/25 7:00:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Announces a Restructuring to Focus on Development of AK006

      Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c

      1/16/24 7:02:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

      – Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m

      1/16/24 7:00:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walker Paul Edward returned 6,147,260 shares to the company (SEC Form 4)

      4 - Allakos Inc. (0001564824) (Issuer)

      5/15/25 4:28:27 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Tomasi Adam returned 533,420 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Allakos Inc. (0001564824) (Issuer)

      5/15/25 4:08:04 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Thomas Dolca

      4 - Allakos Inc. (0001564824) (Issuer)

      5/15/25 4:06:14 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

      SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

      2/11/25 11:30:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Appoints Neil Graham to its Board of Directors

      SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph

      8/30/23 4:05:00 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

      SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well

      8/2/23 4:05:00 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care